J. L. Bainbridge & Co. Inc. lifted its position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 37.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 39,713 shares of the medical instruments supplier's stock after acquiring an additional 10,769 shares during the quarter. Becton, Dickinson and Company makes up approximately 0.9% of J. L. Bainbridge & Co. Inc.'s portfolio, making the stock its 25th biggest position. J. L. Bainbridge & Co. Inc.'s holdings in Becton, Dickinson and Company were worth $9,097,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of Becton, Dickinson and Company by 0.7% during the fourth quarter. Vanguard Group Inc. now owns 26,743,052 shares of the medical instruments supplier's stock valued at $6,067,196,000 after acquiring an additional 184,288 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its position in Becton, Dickinson and Company by 36.1% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 12,126,707 shares of the medical instruments supplier's stock worth $2,751,187,000 after purchasing an additional 3,219,317 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Becton, Dickinson and Company by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 6,351,537 shares of the medical instruments supplier's stock worth $1,437,161,000 after buying an additional 66,024 shares during the period. Massachusetts Financial Services Co. MA grew its position in shares of Becton, Dickinson and Company by 15.1% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 6,175,899 shares of the medical instruments supplier's stock valued at $1,401,126,000 after buying an additional 810,345 shares during the last quarter. Finally, First Eagle Investment Management LLC increased its stake in shares of Becton, Dickinson and Company by 31.4% in the fourth quarter. First Eagle Investment Management LLC now owns 4,426,022 shares of the medical instruments supplier's stock valued at $1,004,132,000 after buying an additional 1,057,879 shares during the period. Institutional investors own 86.97% of the company's stock.
Becton, Dickinson and Company Trading Up 0.5%
Shares of NYSE:BDX traded up $0.86 during mid-day trading on Friday, hitting $170.83. The company had a trading volume of 3,070,304 shares, compared to its average volume of 2,034,779. The firm has a fifty day moving average price of $176.53 and a 200 day moving average price of $209.43. The company has a market capitalization of $48.96 billion, a PE ratio of 12.13, a price-to-earnings-growth ratio of 1.29 and a beta of 0.25. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.13 and a quick ratio of 0.64. Becton, Dickinson and Company has a one year low of $163.33 and a one year high of $251.99.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, beating the consensus estimate of $3.28 by $0.07. The company had revenue of $5.27 billion during the quarter, compared to analyst estimates of $5.35 billion. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. Becton, Dickinson and Company's revenue for the quarter was up 4.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.17 EPS. As a group, research analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.
Becton, Dickinson and Company Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Monday, June 30th. Shareholders of record on Monday, June 9th will be paid a dividend of $1.04 per share. The ex-dividend date is Monday, June 9th. This represents a $4.16 dividend on an annualized basis and a yield of 2.44%. Becton, Dickinson and Company's dividend payout ratio (DPR) is presently 79.39%.
Analyst Ratings Changes
A number of equities analysts recently commented on BDX shares. William Blair lowered Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research note on Thursday, May 1st. Barclays reduced their price objective on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a research note on Tuesday, June 3rd. Wall Street Zen lowered shares of Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a research note on Friday, May 2nd. Citigroup lowered shares of Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and reduced their price objective for the company from $217.00 to $185.00 in a research note on Thursday, May 22nd. Finally, Raymond James Financial lowered shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research note on Friday, May 2nd. Eight investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $219.22.
Read Our Latest Stock Analysis on BDX
Insider Buying and Selling at Becton, Dickinson and Company
In other Becton, Dickinson and Company news, EVP David Shan sold 1,166 shares of the business's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $171.19, for a total transaction of $199,607.54. Following the completion of the sale, the executive vice president now owns 4,575 shares in the company, valued at approximately $783,194.25. The trade was a 20.31% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Michael David Garrison sold 479 shares of the business's stock in a transaction on Wednesday, April 9th. The shares were sold at an average price of $197.28, for a total transaction of $94,497.12. Following the sale, the executive vice president now owns 4,887 shares of the company's stock, valued at $964,107.36. This trade represents a 8.93% decrease in their position. The disclosure for this sale can be found here. 0.36% of the stock is currently owned by company insiders.
About Becton, Dickinson and Company
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Recommended Stories
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
